Cimetidine and other histamine2-receptor antagonist use in relation to risk of breast cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 4, 2005, Pages 1012-1015

  Coogan, Patricia F ^a   Zhang, Yuqing ^a   Palmer, Julie R ^a   Strom, Brian L ^b,c   Rosenberg, Lynn ^a  

^a BOSTON UNIVERSITY   (United States)

^b Ctr Clin Epidemiol Biostatist

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST;

ADULT; AGED; ANAMNESIS; ARTICLE; BREAST CANCER; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG INDUCED CANCER; FEMALE; HOSPITAL ADMISSION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MEDICAL RECORD; PERIODIC MEDICAL EXAMINATION; PRIORITY JOURNAL; BREAST TUMOR; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; HOSPITALIZATION; MIDDLE AGED; STATISTICAL MODEL;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CIMETIDINE; FEMALE; HISTAMINE H2 ANTAGONISTS; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MEDICAL RECORDS; MIDDLE AGED;

EID: 16444377813     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0547     Document Type: Article

References (12)

1. Galbraith RA, Michnovicz JJ. The effects of cimetidine on the oxidative metabolism of estradiol. N Engl J Med 1989;321:269-74.
2. Michnovicz JJ, Galbraith RA. Cimetidine inhibits catechol estrogen metabolism in women. Metabolism 1991;40:170-4.
3. Hankinson SE, Willett WC, Michaud DS, et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999;91:629-34.
4. Hast R, Bernell P, Hansson M. Cimetidine as an immune response modifier. Med Oncol Tumor Pharmacother 1989;6:111-3.
5. Dillman RO, Soori G, DePriest C, et al. Treatment of human solid malignancies with autologous activated lymphocytes and cimetidine: a phase II trial of the Cancer Biotherapy Research Group. Cancer Biother Radiopharm 2003;18:727-33.
6. Schmidt H, Geertsen PF, Fode K, Rytter C, Bastholt L, von der Maase H. Subcutaneous interleukin-2 and interferon-α plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma: a phase II study. Melanoma Res 2000;10:66-77.
7. Jakobisiak M, Lasek W, Golab J. Natural mechanisms protecting against cancer. Immunol Lett 2003;90:103-22.
8. 2-receptor antagonists. Standard therapy for acid-peptic disease. N Engl J Med 1990;323:1672-80.
9. Habel LA, Levin TR, Griedman GD. Cimetidine use and risk of breast, prostate, and other cancers. Pharmacoepidemiol Drug Saf 2000;9:149-55.
10. Rossing MA, Scholes D, Cushing-Haugen KL, Voigt LF. Cimetidine use and risk of prostate and breast cancer. Cancer Epidemiol Biomarkers Prev 2000;9:319-23.
11. Moller H, Lindvig K, Klefter R, Mosbech J, Moller Jensen O. Cancer occurrence in a cohort of patients treated with cimetidine. Gut 1989;30.1558-62.
12. Shapiro S. Case-control Surveillance. 2nd ed. In: Strom BL, editor. Pharmacoepidemiology. Chichester, UK: John Wiley and Sons; 1994. p. 301-22.